NVCT Nuvectis Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1875558 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.8%
TTM EPS YoY-46.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.0%
ROA-57.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $18.15M | $12.92M | $15.38M | $13.23M | $9.54M |
| SG&A expense | $9.42M | $6.93M | $7.52M | $6.01M | $3.35M |
| Operating income | -$27.57M | -$19.85M | -$22.90M | -$19.23M | -$12.89M |
| Net income | -$26.44M | -$19.00M | -$22.26M | -$19.09M | -$12.89M |
| EPS (basic) | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| EPS (diluted) | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 21.81M | 17.11M | 15.56M | 12.66M | 4.27M |
| Balance sheet | |||||
| Cash & equivalents | $31.63M | $18.53M | $19.13M | $19.99M | $5.74M |
| Current assets | $31.71M | $18.61M | $19.18M | $20.41M | $5.83M |
| Total assets | $31.71M | $18.61M | $19.18M | $20.41M | $6.66M |
| Current liabilities | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| Total liabilities | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| Shareholders' equity | $18.41M | $9.71M | $12.20M | $14.22M | -$11.01M |
| Shares outstanding | 25.68M | 19.50M | 17.42M | 15.19M | 4.51M |
| Cash flow statement | |||||
| Operating cash flow | -$16.01M | -$12.25M | -$15.95M | -$13.56M | -$9.50M |
| Investing cash flow | — | $0 | $0 | $0 | — |
| Financing cash flow | $29.11M | $11.65M | $15.09M | $27.81M | $15.25M |
| Stock-based compensation | $6.03M | $4.86M | $4.71M | $1.71M | $1.89M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.